0000000001237849

AUTHOR

Antoine Magnan

showing 6 related works from this author

Optimising experimental research in respiratory diseases: an ERS statement

2018

Experimental models are critical for the understanding of lung health and disease and are indispensable for drug development. However, the pathogenetic and clinical relevance of the models is often unclear. Further, the use of animals in biomedical research is controversial from an ethical perspective.The objective of this task force was to issue a statement with research recommendations about lung disease models by facilitating in-depth discussions between respiratory scientists, and to provide an overview of the literature on the available models. Focus was put on their specific benefits and limitations. This will result in more efficient use of resources and greater reduction in the numb…

Animal Experimentation0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyBiomedical ResearchStatement (logic)Advisory CommitteeseducationMEDLINEDiseaseLung injury[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractHIGHLAND WHITE TERRIERSACUTE LUNG INJURY03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineINBRED MOUSE STRAINSPulmonary fibrosisAnimalsHumansMedicineIntensive care medicineSocieties MedicalALLERGIC AIRWAY INFLAMMATIONbusiness.industryCOMMUNITY-ACQUIRED PNEUMONIACIGARETTE-SMOKE EXPOSURERespiration Disordersmedicine.diseaseDISTRESS-SYNDROME3. Good healthEuropeDisease Models Animal030104 developmental biologyANIMAL-MODELS030228 respiratory systemDrug developmentData qualityARTERIAL-HYPERTENSIONIDIOPATHIC PULMONARY-FIBROSISbusiness
researchProduct

WITHDRAWN: Scaling up strategies of the Chronic Respiratory Disease programme of the European Innovation Partnership on Active and Healthy Ageing (Ac…

2017

Gerontologymedicine.medical_specialtybusiness.industryRespiratory diseaseAlternative medicinemedicine.disease03 medical and health sciences0302 clinical medicine030228 respiratory systemGeneral partnershipAction planmedicineGeneral Earth and Planetary Sciences030212 general & internal medicineHealthy ageingbusinessGeneral Environmental ScienceAlergologia Polska - Polish Journal of Allergology
researchProduct

Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma

2018

Long-term oral corticosteroid (OCS) use in patients with severe asthma is associated with significant adverse effects.This 40-week, randomised, double-blind trial evaluated the OCS-sparing potential of tralokinumab in patients with severe, uncontrolled asthma requiring maintenance OCS treatment plus inhaled corticosteroids/long-acting β2-agonists. Overall, 140 patients were randomised to tralokinumab 300 mg or placebo (n=70 in each group) administered subcutaneously every 2 weeks. The primary end-point was percentage change from baseline in average OCS dose at week 40, while maintaining asthma control. Secondary end-points included proportion of patients with a prescribed maintenance OCS do…

AdultMale0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classAdministration OralPlacebolaw.invention03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled trialAdrenal Cortex HormoneslawInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsAdverse effectAgedInhalationRespiratory tract infectionsbusiness.industryAntibodies MonoclonalMiddle AgedAsthmaClinical trialTreatment Outcome030104 developmental biology030228 respiratory systemDisease ProgressionCorticosteroidFemalebusinessTralokinumabEuropean Respiratory Journal
researchProduct

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe…

2021

Background: ANDHI was done to assess the efficacy of benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms. Methods: This phase 3b, randomised, double-blind, parallel-group, placebo-controlled ANDHI study was completed in adults (aged 18–75 years) with severe eosinophilic asthma with at least 2 exacerbations in the previous year, despite high-dose inhaled corticosteroid plus additional controllers, screening blood eosinophil counts of at least 150 cells per μL, and an Asthma Control Questionnaire 6 (ACQ-6) score of 1·5 or more. Patients who met eligibility criteria were randomly assigned (…

Pulmonary and Respiratory MedicineSpirometryAdultMalemedicine.medical_specialtyExacerbation[SDV]Life Sciences [q-bio]PopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPlaceboAntibodies Monoclonal Humanized03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodInternal medicinemedicineHumans030212 general & internal medicineAnti-Asthmatic AgentsPatient Reported Outcome MeasureseducationSinusitisAsthmaeducation.field_of_studymedicine.diagnostic_testbusiness.industryMiddle Agedmedicine.diseaseBenralizumabAsthma3. Good healthEosinophils030228 respiratory systemchemistryAsthma Control QuestionnaireSpirometryDisease ProgressionQuality of LifeFemalebusiness
researchProduct

Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile techn…

2019

Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second c…

AllergyAllergy:Medicina Básica [Ciências Médicas]asthma -- guidelineAllergic asthmaDECISION-MAKINGAllergic Rhinitis and Its Impact on AsthmaGUIDELINESMedical and Health SciencesMedical Records0302 clinical medicineHealth careImmunology and Allergy030212 general & internal medicineAllergic Rhinitis and Its Impact on Asthma; asthma; Change management; rhinitis; Immunology and Allergy; ImmunologyMASK-RHINITISComputingMilieux_MISCELLANEOUSRinitismobilne aplikacijeupravljanje spremembMedical recordGLOBAL STRATEGYWORK PRODUCTIVITYTelemedicinemobile applications3. Good healthAsma alérgicarhiniti1107 ImmunologyCiências Médicas::Medicina Básicaklinične potiallergic -- guidelineLife Sciences & BiomedicineHumanPATIENT PARTICIPATIONAllergic RhinitisTelemedicinemedicine.medical_specialtyanimal structuresmultimorbidityEUROPEAN INNOVATION PARTNERSHIPImmunologyChange Management[object Object]Settore MED/10 - Malattie Dell'Apparato RespiratorioAsthma/diagnosisCHRONIC DISEASESMACVIA-ARIA03 medical and health sciencesrhinitismedicinemultimorbidnostQUALITYHumanscritical pathwaysastma -- smernicaPatient participationAsmaudc:616.2AsthmaScience & TechnologyARIAbusiness.industryAllergic Rhinitis and Its Impact on Asthma; asthma; Change management; rhinitis; Change Management; Humans; Medical Records; Asthma; Multimorbidity; Rhinitis Allergic; TelemedicineSettore MED/09 - MEDICINA INTERNAchange managementMultimorbidityMobile Airways Sentinel Network (MASK) Study GroupGuidelineasthmata3121medicine.diseaseRinite alérgicaRhinitis AllergicRhinitis Allergic/diagnosisAsthmaIntegrated carealergijski rinitis -- smernicaAllergic Rhinitis and Its Impact on Asthma asthma Change management rhinitis Immunology and Allergy Immunology030228 respiratory systemFamily medicine3121 General medicine internal medicine and other clinical medicineMedical RecordClinical Medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyImpact on AsthmaJournal of Allergy and Clinical Immunology
researchProduct

Cabbage and fermented vegetables: from death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19

2021

International audience; Large differences in COVID-19 death rates exist between countries and between regions of the same country. Some very low death rate countries such as Eastern Asia, Central Europe, or the Balkans have a common feature of eating large quantities of fermented foods. Although biases exist when examining ecological studies, fermented vegetables or cabbage have been associated with low death rates in European countries. SARS-CoV-2 binds to its receptor, the angiotensin-converting enzyme 2 (ACE2). As a result of SARS-CoV-2 binding, ACE2 downregulation enhances the angiotensin II receptor type 1 (AT1 R) axis associated with oxidative stress. This leads to insulin resistance …

ARIA groupAntioxidantMediterranean dietmedicine.medical_treatmentBrassicasulforaphaneMESH: Angiotensin-Converting Enzyme 2ReviewcabbageAntioxidants0302 clinical medicine10183 Swiss Institute of Allergy and Asthma ResearchVegetableskimchiFood sciencekimči0303 health sciencesMESH: NF-E2-Related Factor 23. Good healthAngiotensin-converting enzyme 22723 Immunology and Allergyfermentirana zelenjavaMESH: EcologyKeywords: Angiotensin converting enzyme 2NF-E2-Related Factor 2KEAP1-NRF2 SYSTEMImmunologyReviewsBrassicaNRF203 medical and health sciencesudc:578:635.34:663.15:COVID‐19angiotensin-converting enzyme 2CorrespondenceHumansMESH: SARS-CoV-2LactobacilluINTERMITTENT HYPOXIA2403 ImmunologyScience & TechnologyMESH: HumansAngiotensin II receptor type 1koronavirusMESH: Antioxidantsmedicine.disease030228 respiratory systemchemistryFermentationAllergymedicine.disease_causechemistry.chemical_compoundLINKING GUT MICROBIOTALactobacillalesLactobacillusImmunology and AllergyMESH: COVID-19Angiotensin converting enzyme 2030212 general & internal medicineOXIDATIVE STRESS[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyKeywords: Angiotensin converting enzyme 2; COVID-19; Lactobacillus; cabbage; diet; fermented vegetable; kimchi; sulforaphane.angiotensin-converting enzyme 2; cabbage; COVID-19; diet; fermented vegetable; kimchi; Lactobacillus; sulforaphane2. Zero hungerFOODSEcologyLactobacillalesMortality rate10177 Dermatology ClinicMEDITERRANEAN DIET1107 ImmunologyLife Sciences & Biomedicinefermented vegetable610 Medicine & healthSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologyMESH: FermentationMESH: Gastrointestinal MicrobiomeInsulin resistanceMESH: DietDownregulation and upregulationmedicine030304 developmental biologySARS-CoV-2COVID-19MESH: BrassicaCOVID-19; Lactobacillus; angiotensin-converting enzyme 2; cabbage; diet; fermented vegetable; kimchi; sulforaphane; Angiotensin-Converting Enzyme 2; Antioxidants; COVID-19; Diet; Ecology; Gastrointestinal Microbiome; Humans; Lactobacillales; NF-E2-Related Factor 2; Brassica; Fermentation; SARS-CoV-2; Vegetablesbiology.organism_classificationMESH: VegetablesDYSFUNCTIONDietGastrointestinal MicrobiomeLactobacillusMESH: Lactobacillalesangiotensin-converting enzyme 2 cabbage COVID-19 diet fermented vegetable kimchi Lactobacillus sulforaphanedietOxidative stressSulforaphane
researchProduct